The Latest Breaking News from Zoetis

As the U.S. presidential election nears, here are three defensive dividend-paying stocks to help shield your portfolio from pre-election volatility.

Despite Zoetis’s underperformance relative to the Dow Jones Industrials Average over the past year, Wall Street analysts remain optimistic about the stock’s prospects.

Amid a broader market rotation out of Big Tech stocks, investors can consider these three top-rated healthcare stocks with double-digit upside potential.

The pharmaceutical industry’s long-term growth is fueled by a surge in demand for personalized medicine, favorable R&D initiatives, and the adoption of cutting-edge technologies. Hence, it could be ideal to buy fundamentally solid pharma stocks Zoetis (ZTS), Viatris (VTRS), and Bristol-Myers Squibb (BMY) poised for blockbuster return potential. Keep reading….

Despite Zoetis significantly trailing behind the Nasdaq Composite over the past three months, analysts seem extremely bullish on the stock’s prospects due to its robust product pipeline and global reach.

In today's uncertain economic landscape, marked by high inflation, high rates, and global uncertainty, here are three resilient 'Strong Buy' dividend stocks that investors can consider for long-term returns.

At the Fortune Future of Finance conference, the leaders discussed the key expectations for their positions.

If you're wondering where to invest in these uncertain times, Goldman Sachs has dropped some hints with their top five stock picks that might just weather the storm.

Using the POWR Ratings to power profits on a POWR Pairs trade in Zoetis (ZTS) and Air Products (APD).